{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:50:36Z","timestamp":1791449436696,"version":"4.3.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s13555-026-01887-8","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:02:47Z","timestamp":1787238167000},"page":"5013-5035","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Treatment Patterns, Healthcare Resource Utilisation, and Costs in Biologic-Na\u00efve Patients with Moderate-to-Severe Psoriasis Treated with Biologics in France"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0797-6570","authenticated-orcid":false,"given":"Thierry","family":"Passeron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Ta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Hospital","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3088-7453","authenticated-orcid":false,"given":"Keith A.","family":"Betts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1360-8133","authenticated-orcid":false,"given":"Maryaline","family":"Catillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calvin","family":"Plays","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2995-7928","authenticated-orcid":false,"given":"Denis","family":"Jullien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"issue":"11","key":"1887_CR1","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1111\/jdv.14959","volume":"32","author":"M-A Richard","year":"2018","unstructured":"Richard M-A, Corgibet F, Beylot-Barry M, et al. Sex- and age-adjusted prevalence estimates of five chronic inflammatory skin diseases in France: results of the \u00ab\u202fOBJECTIFS PEAU\u202f\u00bb study. J Eur Acad Dermatol Venereol. 2018;32(11):1967\u201371.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1887_CR2","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.annder.2020.02.015","volume":"148","author":"MA Richard","year":"2021","unstructured":"Richard MA, Sei JF, Philippe C, et al. Prevalence of comorbidities in atopic dermatitis and psoriasis in the French population. Ann Dermatol Venereol. 2021;148(1):28\u201333.","journal-title":"Ann Dermatol Venereol"},{"issue":"19","key":"1887_CR3","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945\u201360.","journal-title":"JAMA"},{"issue":"11","key":"1887_CR4","doi-asserted-by":"publisher","first-page":"5203","DOI":"10.1007\/s12325-022-02305-z","volume":"39","author":"M-A Richard","year":"2022","unstructured":"Richard M-A, Aubin F, Beneton N, et al. Moderate psoriasis in clinical practice: French expert consensus using a modified Delphi method. Adv Ther. 2022;39(11):5203\u201315.","journal-title":"Adv Ther"},{"issue":"9","key":"1887_CR5","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1111\/j.1468-3083.2010.03600.x","volume":"24","author":"N Meyer","year":"2010","unstructured":"Meyer N, Paul C, Feneron D, et al. Psoriasis: an epidemiological evaluation of disease burden in 590 patients. J Eur Acad Dermatol Venereol. 2010;24(9):1075\u201382.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"1887_CR6","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1111\/jdv.16915","volume":"34","author":"A Nast","year":"2020","unstructured":"Nast A, Smith C, Spuls PI, et al. EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris - part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34(11):2461\u201398.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1887_CR7","first-page":"1","volume":"00","author":"M Masson Regnault","year":"2025","unstructured":"Masson Regnault M, Brenaut E, Marniquet M-E, et al. French guidelines on systemic treatments for moderate-to-severe psoriasis in adults: update 2025. J Eur Acad Dermatol Venereol. 2025;00:1\u201317.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"1887_CR8","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1111\/jdv.18409","volume":"36","author":"R Curmin","year":"2022","unstructured":"Curmin R, Guillo S, De Rycke Y, et al. Switches between biologics in patients with moderate-to-severe psoriasis: results from the French cohort PSOBIOTEQ. J Eur Acad Dermatol Venereol. 2022;36(11):2101\u201312.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1887_CR9","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","volume":"156","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Puig L, Joshi A, et al. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020;156(3):258\u201369.","journal-title":"JAMA Dermatol"},{"key":"1887_CR10","volume":"8","author":"E Sbidian","year":"2025","unstructured":"Sbidian E, Chaimani A, Guelimi R, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2025;8:Cd011535.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"1887_CR11","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jamadermatol.2022.0364","volume":"158","author":"L Pina Vegas","year":"2022","unstructured":"Pina Vegas L, Penso L, Claudepierre P, Sbidian E. Long-term persistence of first-line biologics for patients with psoriasis and psoriatic arthritis in the French health insurance database. JAMA Dermatol. 2022;158(5):513\u201322.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"1887_CR12","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1080\/09546634.2018.1480746","volume":"30","author":"H Roche","year":"2019","unstructured":"Roche H, Bouiller K, Puzenat E, et al. Efficacy and survival of biologic agents in psoriasis: a practical real-life 12-year experience in a French dermatology department. J Dermatolog Treat. 2019;30(6):540\u20134.","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"1887_CR13","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/bjd.16809","volume":"180","author":"E Sbidian","year":"2019","unstructured":"Sbidian E, Mezzarobba M, Weill A, Coste J, Rudant J. Persistence of treatment with biologics for patients with psoriasis: a real-world analysis of 16 545 biologic-na\u00efve patients from the French National Health Insurance database (SNIIRAM). Br J Dermatol. 2019;180(1):86\u201393.","journal-title":"Br J Dermatol"},{"issue":"9","key":"1887_CR14","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1111\/jdv.12318","volume":"28","author":"M Le Moigne","year":"2014","unstructured":"Le Moigne M, Sommet A, Lapeyre-Mestre M, et al. Healthcare cost impact of biological drugs compared with traditional systemic treatments in psoriasis: a cohort analysis in the French insurance database. J Eur Acad Dermatol Venereol. 2014;28(9):1235\u201344.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1887_CR15","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.therap.2024.05.003","volume":"79","author":"O Maillard","year":"2024","unstructured":"Maillard O, Bun R, Laanani M, et al. Use of the French National Health Data System (SNDS) in pharmacoepidemiology: a systematic review in its maturation phase. Therapies. 2024;79(6):659\u201369.","journal-title":"Therapies"},{"issue":"6","key":"1887_CR16","doi-asserted-by":"publisher","first-page":"adv00473","DOI":"10.2340\/00015555-3765","volume":"101","author":"E Sbidian","year":"2021","unstructured":"Sbidian E, Mezzarobba M, Shourick J, et al. Choice of systemic drugs for the management of moderate-to-severe psoriasis: a cross-country comparison based on national health insurance data. Acta Derm Venereol. 2021;101(6):adv00473.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"1887_CR17","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2176708","volume":"34","author":"S Thai","year":"2023","unstructured":"Thai S, Zhuo J, Zhong Y, et al. Real-world treatment patterns and healthcare costs in patients with psoriasis taking systemic oral or biologic therapies. J Dermatolog Treat. 2023;34(1):2176708.","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"1887_CR18","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s13555-023-01064-1","volume":"14","author":"Y Tada","year":"2024","unstructured":"Tada Y, Soliman AM, Ishii K, et al. Real-world discontinuation and switching patterns for interleukin-inhibitor treatments in patients with moderate-to-severe psoriasis in Japan. Dermatol Ther. 2024;14(1):99\u2013114.","journal-title":"Dermatol Ther"},{"key":"1887_CR19","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jdrv.2024.06.007","volume":"1","author":"A Bagit","year":"2024","unstructured":"Bagit A, Sood S, Alli S, et al. The efficacy and safety of switching between interleukin inhibitors in psoriasis therapy: a systematic review. JAAD Rev. 2024;1:97\u20139.","journal-title":"JAAD Rev"},{"issue":"1","key":"1887_CR20","doi-asserted-by":"publisher","first-page":"2521082","DOI":"10.1080\/09546634.2025.2521082","volume":"36","author":"L Zhang","year":"2025","unstructured":"Zhang L, Zhao X, Li W, Sun Y, Liu H. Switching biologic agent in patients with psoriasis: a systematic review and meta-analysis. J Dermatolog Treat. 2025;36(1):2521082.","journal-title":"J Dermatolog Treat"},{"issue":"5, Part B","key":"1887_CR21","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.ijwd.2021.08.010","volume":"7","author":"M Esposito","year":"2021","unstructured":"Esposito M, Calianno G, Lappi A, Fargnoli MC. Treatment of severe psoriasis during pregnancy and breastfeeding: a therapeutic challenging case. Int J Womens Dermatol. 2021;7(5, Part B):832\u20134.","journal-title":"Int J Womens Dermatol"},{"issue":"8","key":"1887_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0220868","volume":"14","author":"LM Sawyer","year":"2019","unstructured":"Sawyer LM, Malottki K, Sabry-Grant C, et al. Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response. PLoS ONE. 2019;14(8):e0220868.","journal-title":"PLoS ONE"},{"issue":"1","key":"1887_CR23","doi-asserted-by":"publisher","first-page":"2200869","DOI":"10.1080\/09546634.2023.2200869","volume":"34","author":"JJ Wu","year":"2023","unstructured":"Wu JJ, Patel M, Zeng F, et al. Real-world dose escalation of biologics for moderate-to-severe psoriasis in the United States. J Dermatolog Treat. 2023;34(1):2200869.","journal-title":"J Dermatolog Treat"},{"issue":"5","key":"1887_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/exd.15067","volume":"33","author":"Y Tada","year":"2024","unstructured":"Tada Y, Soliman AM, Ishii K, et al. Dose escalation of biologic treatment in patients with moderate-to-severe psoriasis in Japan. Exp Dermatol. 2024;33(5):e15067.","journal-title":"Exp Dermatol"},{"issue":"10","key":"1887_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0258182","volume":"16","author":"KW Scott","year":"2006","unstructured":"Scott KW, Liu A, Chen C, et al. Healthcare spending in U.S. emergency departments by health condition, 2006-2016. PLoS ONE. 2006;16(10):e0258182.","journal-title":"PLoS ONE"},{"issue":"4","key":"1887_CR26","first-page":"479","volume":"25","author":"SR Feldman","year":"2019","unstructured":"Feldman SR, Tian H, Wang X, Germino R. Health care utilization and cost associated with biologic treatment patterns among patients with moderate to severe psoriasis: analyses from a large U.S. claims database. J Manag Care Spec Pharm. 2019;25(4):479\u201388.","journal-title":"J Manag Care Spec Pharm"},{"key":"1887_CR27","doi-asserted-by":"publisher","first-page":"S371","DOI":"10.1016\/j.jval.2018.09.2214","volume":"21","author":"P Blin","year":"2018","unstructured":"Blin P, Lasalle R, Thurin N, et al. PRM93 - SNDS, the French nationwide claims database: a powerful tool for pharmacoeconomy and pharmacoepidemiology. Value Health. 2018;21:S371.","journal-title":"Value Health"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01887-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01887-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01887-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:00:46Z","timestamp":1791446446000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01887-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1887"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01887-8","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"assertion":[{"value":"10 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Thierry Passeron has received personal fees from AbbVie, ACM Pharma, Almirall, Boehringer Ingelheim, Bristol Myers Squibb, Calypso, Celgene, Galderma, Genzyme\/Sanofi, GlaxoSmithKline, Incyte, Janssen, LEO Pharma, Eli Lilly, Novartis, Roivant Sciences Ltd, Sanofi, Sun Pharmaceuticals, and VYNE Therapeutics and is a co-founder of NIKAIA Pharmaceuticals and founder of SUNLUTION. Richard Ta and V\u00e9ronique Hospital are employees of AbbVie and may hold stocks\/stock options. Keith Betts and Calvin Plays are employees of Analysis Group, Inc., which received payment from AbbVie Inc. for participation in this research. Maryaline Catillon is a former employee of Analysis Group, Inc., which received payment from AbbVie Inc. for participation in this research. Denis Jullien is a consultant for and has received personal fees from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Janssen-Cilag, Leo, Lilly, MEDAC, Novartis, and UCB.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval issued by the Comit\u00e9 \u00c9thique et Scientifique pour les Recherches, les \u00c9tudes et les \u00c9valuations dans le domaine de la Sant\u00e9 (CESREES) on June 15, 2023 (TPS No. 12242458).","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}